Table 1.
Demographic and Clinical Characteristics of the Patients at Baseline.*
| Characteristic | Nivolumab plus Ipilimumab (N = 94) |
|---|---|
| Median age (range) — yr | 59 (22–81) |
| Sex — no. (%) | |
| Male | 65 (69) |
| Female | 29 (31) |
| Lactate dehydrogenase — no. (%) | |
| At or below the upper limit of the normal range | 55 (59) |
| Above the upper limit of the normal range | 39 (41) |
| PD-L1 expression — no. (%) | |
| ≥1% | 41 (44) |
| <1% | 34 (36) |
| Could not be evaluated | 19 (20) |
| Stereotactic radiotherapy before study entry — no. (%) | |
| Yes | 8 (9) |
| No | 86 (91) |
| No. of target lesions at pretreatment tumor assessment — no. of patients (%) | |
| No lesions | 1 (1)† |
| 1 Lesion | 49 (52) |
| 2 Lesions | 23 (24) |
| ≥3 Lesions | 21 (22) |
*
Percentages may not total 100 because of rounding. PD-L1 denotes programmed death ligand 1.
†
The inclusion of this patient was a protocol deviation.